3D Map of PC2 to Jump-Start Drug Discovery Efforts in Polycystic Kidney Disease

Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes autosomal dominant polycystic kidney disease (ADPKD) when mutated, in an article published this week in Nature Structural and Molecular... - December 21, 2016

Oxford AHSN Recognizes the SGC with Its Annual Public-Private Collaboration Award

Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award. - October 11, 2016

The SGC Releases Enabling Information to Accelerate Drug Discovery

Data packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria. - September 13, 2016

Press Releases 1 - 3 of 3